Rocket Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Rocket Pharmaceuticals

27/02/2025 22:02

Rocket Pharmaceuticals Inc RCKT.OQ reported a quarterly adjusted loss of 62 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -64 cents.  The mean expectation of sixteen analysts for the quarter was for a loss of 72 cents per share. Wall Street expected results to range from -80 cents to -62 cents per share.

Reported revenue was zero​; analysts expected $31.30 thousand.

Rocket Pharmaceuticals Inc's reported EPS for the quarter was a loss of 62 cents​.

The company reported a quarterly loss of $60.33 million.

Rocket Pharmaceuticals Inc shares had fallen by 24.3% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 2.5% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Rocket Pharmaceuticals Inc is $39.00

This summary was machine generated from LSEG data February 27 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.72
-0.62
Beat
Sep. 30 2024
-0.76
-0.71
Beat
Jun. 30 2024
-0.72
-0.74
Missed
Mar. 31 2024
-0.68
-0.66
Beat